CLAIMS

1. A heterotandem bicyclic peptide complex comprising:

(a) a first peptide ligand, or a pharmaceutically acceptable salt thereof, which binds to Nectin-4 and which has the sequence C_iP[1Nal][dD]C_{ii}M[HArg]DWSTP[HyP]WC_{iii} (SEQ ID NO: 1; BCY8116); conjugated via an N-(acid-PEG_3)-N-bis(PEG_3-azide) linker to

(b) two second peptide ligands, or pharmaceutically acceptable salts thereof, which bind to CD137 both of which have the sequence Ac-C_i[tBuAla]PE[D-Lys(PYA)]PYC_{ii}FADPY[Nle]C_{iii}-A (SEQ ID NO: 2; BCY8928);

wherein each of said peptide ligands comprise a polypeptide comprising three reactive cysteine groups (C_i, C_{ii} and C_{iii}), separated by two loop sequences, and a molecular scaffold which is 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA) and which forms covalent bonds with the reactive cysteine groups of the polypeptide such that two polypeptide loops are formed on the molecular scaffold;

wherein Ac represents acetyl, HArg represents homoarginine, HyP represents trans-4-hydroxy-L-proline, 1Nal represents 1-naphthylalanine, tBuAla represents t-butyl-alanine, PYA represents 4-pentynoic acid and Nle represents norleucine.

2. The heterotandem bicyclic peptide complex according to claim 1 which is BCY11863:



BCY00011863

3. The heterotandem bicyclic peptide complex as defined in claim 1 or claim 2, wherein the pharmaceutically acceptable salt is selected from the free acid or the sodium, potassium, calcium, ammonium salt.

4. A pharmaceutical composition which comprises the heterotandem bicyclic peptide complex of any one of claims 1 to 3 in combination with one or more pharmaceutically acceptable excipients.

5. The heterotandem bicyclic peptide complex as defined in any one of claims 1 to 3 for use in preventing, suppressing or treating cancer.

6. Use of a heterotandem bicyclic peptide complex as defined in any one of claims 1 to 3 in the manufacture of a medicament for treating cancer, wherein the heterotandem bicyclic peptide complex is to be administered at a dosage frequency which does not sustain plasma concentrations of said complex above the *in vitro* EC_{50} of said complex.